logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8951972 B1

PDFFull Text
Date of Patent:
Feb. 10, 2015

Filed:

Nov. 14, 2011

Fgfr1 extracellular domain combination therapies for lung cancer

Applicants:

LI Long, Lafayette, CA (US);

Thomas Brennan, San Jose, CA (US);

Inventors:

Li Long, Lafayette, CA (US);

Thomas Brennan, San Jose, CA (US);

Assignee:

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

Attorney:

Casimir Jones, S.C.

Primary Examiner:

Elly-Gerald Stoica

Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/00 (2006.01); C12P 21/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 38/38 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/475 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 33/24 (2006.01);
U.S. Cl.
CPC ...
A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 38/38 (2013.01); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61K 31/475 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 33/24 (2013.01);
Abstract

Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

Find Patent Forward Citations

Loading…